Japan’s Ministry of Health, Labour and Welfare approved Myriad Genetics’ MyChoice as a companion diagnostic for selecting prostate cancer patients who may benefit from AstraZeneca’s PARP inhibitor Lynparza. The approval positions Myriad’s test to support treatment decision-making in a defined biomarker population. MyChoice is intended to identify patients likely to respond based on genetic factors linked to Lynparza use. The decision adds a further data point to the growing role of CDx tools in oncology, where therapy selection is increasingly tied to tumor genetics.